Macy’s employees honored by Peoria Fire and Medical for saving customer’s life

Employees of the Macy’s at Arrowhead Mall were honored Wednesday by Peoria Fire and Medical after they used CPR to save a customer’s life.

PEORIA, AZ (3TV/CBS 5) — Employees at the Macy’s in Arrowhead Mall were recognized Wednesday morning for their quick thinking that helped save a woman’s life.

According to Peoria Fire and Medical, Reba Mason was shopping at the Macy’s on July 10 when she fell unconscious. She was in full cardiac arrest, not breathing and didn’t have a pulse.


[READ MORE: Cancer warrior says she owes her life to Macy’s employees in Peoria]

Several managers at the Macy’s who had taken CPR training classes jumped into action and began doing CPR on her.

Peoria-Fire and Medical paramedics responded and took over CPR. Mason regained her pulse and was able to breathe on her own while on the way to the hospital.

Mason is currently battling breast cancer and is recovering from the cardiac event.

Peoria-Fire and Medical honored the employees and hopes that this will encourage other corporate offices, small businesses and organizations to learn CPR.

“We are so proud of Princella, Rosy, Claudette and Amy, our Macy’s Arrowhead colleagues, for their quick action and heroism last week. We are especially grateful for Reba’s recovery,” said Colleen Liard, store manager at Macy’s Arrowhead. “At Macy’s, our executives are trained in CPR specifically for situations such as this, and we are delighted that they were able to successfully put their training into practice.”




Valley woman praises Macy’s workers at Arrowhead Mall for saving her life

By: Angie Koehle

Reba Mason jokes that shoe shopping saved her life last week. Mason is a breast cancer patient and the founder of Reba’s Vision, a non-profit to help survivors with expenses. She just left an appointment on Tuesday after having the pain medicine changed in her implanted pump. She later learned something went terribly wrong.


GLENDALE, AZ — Reba Mason jokes that shoe shopping saved her life last week.

“I don’t remember driving to Macy’s. That’s the scary part. I could’ve killed someone,” Mason said.

Mason is a breast cancer patient and the founder of Reba’s Vision, a non-profit to help survivors with expenses. She just left an appointment on Tuesday after having the pain medicine changed in her implanted pump. She later learned something went terribly wrong.

“A little bit of medicine leaked into my body,” she said.

Essentially it caused her to overdose and go into cardiac arrest. But fortunately, she wasn’t at home alone, where she would’ve normally been. She was right in the middle of the Macy’s at Arrowhead Mall.

“These people jumped into action with no thought about it. They just did it,” she said.

It turns out those people were Macy’s managers. Coincidentally, they recently had mandatory CPR training, and by chance, there was a manager meeting at that very time, so all of the managers were there. When a call went out over the loudspeaker for a customer in distress, the freshly-trained staff rushed to her. They started CPR and worked on her for ten minutes until paramedics from Peoria could get there.

Though the mall is in Glendale, Peoria’s crew was closer. She can’t begin to express her gratitude for each one of the people who helped her.

“There’s not enough gratitude in the world to tell you just how thankful and grateful I am,” she said.

When Mason woke up in ICU, she was given the two pair of shoes she bought. She later found out she actually purchased three pairs. She looks forward to picking up the third pair and meeting those workers again, but under much better circumstances.

“My husband wouldn’t have a wife today if not for all of them,” she said.

A spokesperson for Peoria fire confirms the employees saved her life. The department plans to honor them at an event this week.





Party Invitation

Thusday, June 13, 2019 5:00 pm – 7:30 pm

Glendale Women’s Club
7032 N. 56th Avenue

You’re Invited to Celebrate with Us!

Reba’s Vision Grand Ribbon Cutting

With the Glendale Chamber of Commerce

DJ Curtis Whipple providing the tunes.
Raffle Prizes, Food, Adult Beverages
Wine samples Provided By Wines By Humanity Diana Pompa


Watch “Ironwood Survivors Celebration Breakfast Celebration in Glendale May 4, 2019” on YouTube


What a amazing day we had at Ironwood cancer center.

Our next event is the Glendale Women’s club on Wednesday I will be speaking at 11:30

Lookimg forward to a wonderful week


– Reba

New ‘smart drug’ shows promise for metastatic triple-negative breast cancer

A new “smart drug” has shown promise for women with metastatic triple-negative breast cancer, based on data from a clinical trial at NewYork-Presbyterian/Columbia’s Herbert Irving Comprehensive Cancer Center and other centers. The data from the trial were published today in the New England Journal of Medicine.


“I think this drug has the potential to change practice, because the data looks so compelling, even with the relatively small number of patients in the trial,” says Kevin Kalinsky, MD, MS, assistant professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, an oncologist at New York-Presbyterian/Columbia University Irving Medical Center, and the paper’s senior author.


“There’s an unmet need for patients with metastatic triple-negative breast cancer, and we see significant tumor shrinkage with this new therapy,” Kalinsky adds.


Triple-negative breast cancer is an aggressive disease and is more common, relative to other breast cancers, in young women and African-American women. Triple-negative breast cancers do not express the estrogen receptor, progesterone receptor, or HER2. Thus, historically, treatments only included chemotherapy for triple-negative breast cancer and not targeted therapy, such as hormone therapy or Herceptin.


The drug, sacituzumab govitecan, is part of an emerging class of “smart drugs” designed to deliver a toxic payload directly to tumor cells. The drug is a fusion of an antibody that recognizes a protein expressed by breast cancer cells known as trop2 and the metabolite of an established chemotherapy drug (irinotecan), SN-38. The antibody delivers SN-38 directly to the cancer cell.


Kalinsky says that “with this smart drug, we can deliver a much higher dose of the payload since we’re sending it directly to the cancer cells.”


The trial tested the drug in 108 women with metastatic triple-negative breast cancer who had already been through two or more previous treatment regimens.


By the time a patient has started her third or fourth treatment regimen, the chance of a response is low. Sacituzumab govitecan, however, produced a better response rate in pre-treated patients than what has been historically seen with other standard therapies.


Overall, 33 percent of patients responded to the drug; the median duration of response was 7.7 months; and median overall survival was 13 months. [Note: The trial only tested sacituzumab govitecan; a randomized Phase II/III clinical trial comparing sacituzumab govitecan to other drugs is ongoing].


“We saw significant tumor shrinkage with the drug, and it took longer for the cancer to progress compared to other drugs commonly used to treat metastatic triple-negative breast cancer,” Kalinsky says. Nine long-term responders remained free of disease progression for over a year.


“Having smaller tumors can be incredibly meaningful to a patient’s quality of life,” Kalinsky adds. “When tumors shrink, patients are more likely to experience improvement in symptoms, like pain.”


The main side effects seen in the trial were hair loss, diarrhea, and fatigue, but only 3 percent of patients had to stop taking the drug due to adverse events.


“Importantly, the drug did not cause neuropathy, the numbness and tingling that can be quite painful and limiting for patients,” Kalinsky says. “Neuropathy can make it difficult to dress oneself, or even walk. It is promising to have an active treatment that does not have neuropathy as a side effect.”


The drug is also being tested in other types of breast cancer, bladder cancer, and prostate cancer.


“We are excited to have participated in the early development of this novel drug, which we hope will change the treatment paradigm for patients with metastatic triple-negative breast cancer,” says Gary Schwartz, MD, chief of hematology/oncology at New York-Presbyterian/Columbia University Irving Medical Center and deputy director of New York-Presbyterian/Columbia’s Herbert Irving Comprehensive Cancer Center.


The paper is titled, “Sacituzumab Govitecan-hziy for Refractory Metastatic Triple Negative Breast Cancer,” and was published online in the New England Journal of Medicine.


Other authors: Aditya Bardia (Massachusetts General Hospital Cancer Center, Harvard Medical School), Ingrid Mayer (Vanderbilt University), Linda T. Vahdat (Memorial Sloan Kettering Cancer Center), Sara Tolaney (Dana-Farber Cancer Institute), Steven Isakoff (Massachusetts General Hospital), Jennifer Diamond (University of Colorado), Joyce O’Shaughnessy (US Oncology, Baylor Sammons Cancer Center), Rebecca Moroose (UF Health Cancer Center-Orlando Health), Alessandro Santin (Yale University), Vandana Abramson (Vanderbilt-Ingram Cancer Center), Nikita Shah (UF Health Cancer Center-Orlando Health), Hope Rugo (University of California, San Francisco), David Goldenberg (Immunomedics), Ala Sweidan (Immunomedics), Robert Iannone, Robert (Immunomedics), Sara Washkowitz, Sara (Immunomedics), Robert Sharkey (Immunomedics), William Wegener (Immunomedics).


The trial, Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers, is sponsored by Immunomedics, Inc. Identifier: NCT01631552. Study Chair: Aditya Bardia, MD, Massachusetts General Hospital and Harvard Medical School.



Story Source:

Materials provided by Columbia University Irving Medical CenterNote: Content may be edited for style and length.


My hope bag event


On Saturday March the 3rd we were one of the lucky participants in the my hope bag a event in Phoenix. It was Reba’s Vision honor to Be able to provide women Witty amazing resources that we have available thanks to other survivors. We were able to hand out for wigs and over 10 hats and beanies. It is my extreme honor to be blessed to be able to do this through our foundation.



6 Women Share Why They ‘Went Flat’ After Their Mastectomies

Roughly 60 percent of women who undergo a mastectomy will opt to have reconstructive surgery to recover the familiar “look” of having breasts. However, there’s a growing movement toward going “flat” after a mastectomy.

The six women in the video below all chose to go flat after breast cancer. And, as it turns out, there might be some good reasons to join them.

For some women, like Melanie Testa, having breast reconstruction or wearing breast forms can feel like a lie. “I just don’t want to present two bodies,” she says. “I don’t want to walk out of my home with a breasted body and then return to my home and remove my breast and then have a flat body.”

For others, breast reconstruction simply isn’t an option, or at least it isn’t nearly as simple as it sounds. Cost can be a factor, or health issues may make any additional surgeries too risky. Marianne Duquette Quoso wanted implants and got them—but after several infections, she became one of the roughly 20 percent of women whose implants cause issues for them, and she decided to have them removed. Those who have post-reconstruction issues but choose to keep their implants may have trouble sleeping on their stomachs, deal with multiple infections, or experience other complications and discomfort.

Modern breast implants are often praised for looking and feeling real, but these ladies say they don’t always feel real (or even good) from the inside. Samantha West says, “In terms of sexuality, scars are very tender things. There’s feeling in my chest, and it’s still an erogenous zone, which doesn’t happen with implants.”

Dr. Deborah Axelrod says she believes the majority of women will still prefer reconstruction over going flat in the future. “We feel that if we’re going to take a body part off, that we should then replace it with something that looks just as good,” she says. “It’s the image of our bodies. We want to be whole.”

It should be each individual woman’s choice whether or not to have reconstructive surgery, but we can’t help but applaud the message the “going flat” movement sends to the world. Melanie sums it up by saying, “My body is good enough.”

Rebecca Pine adds, “Beauty is something in the mind and in the heart. We’re just as feminine, we’re just as much women as we were beforehand.”

Learn more about the brave women below and their incredible stories in the video below.